Skip to main content
Signal8

ELI LILLY & Co (LLY)

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Sector: Pharmaceutical Preparations

Industry: Drug Manufacturers - General

Eli Lilly and Company logo

Eli Lilly and Company

NYSE:LLYHealthcare
-2.12%$1279.00
AH Close$1279.00+0.00%vs close
Mkt Cap$1.2T
Float849.67M
O/S941.36M
Inst Own71.8%
Div Yield0.53%
Dilution
Historical Data
DateOpenHighLowCloseVolume
Key Metrics
Market Cap$1.204T
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership71.75%

based on 941.36M shares outstanding

SectorHealthcare
IndustryDrug Manufacturers - General
ExchangeNYSE
CountryUSUS
IPO Date-
Shares Outstanding941.36M
Float849.67M
Company Overview

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world.

Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Leadership

Anat Hakim

Executive Vice President, General Counsel & Secretary

Carolyn R. Bertozzi, Ph.D.

Dan Skovronsky, M.D., Ph.D.

Executive Vice President, Chief Scientific and Product Officer and President, Lilly Research Labs

Dave Ricks

Chair, President, and Chief Executive Officer

Employees

50K+

Country

US

Sector

Healthcare

Website

lilly.com

Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
No price targets available
Ratings Distribution
BUY
33
HOLD
9
SELL
3
TOTAL45
Insider Trading
InsiderTypeShares
Sulzberger Gabrielle profile photoSulzberger GabrielleGrant/Award3.998
LUCIANO JUAN R profile photoLUCIANO JUAN RGrant/Award12.833
Alvarez Ralph profile photoAlvarez RalphGrant/Award10.011
Fyrwald J Erik profile photoFyrwald J ErikGrant/Award7.995
LUCIANO JUAN R profile photoLUCIANO JUAN RGrant/Award13.664
Alvarez Ralph profile photoAlvarez RalphGrant/Award10.659
Shareholders
71.8%
Institutional
(4680)
0.1%
Insiderⓘ
(27)
9.6%
5%+ Owners
(1)
18.5%
Unattributed (incl. retail)ⓘ
Institutional71.8%
Insider0.1%
5%+ Beneficial9.6%
Unattributed (incl. retail)18.5%
Sources: 13F, Form 4, 13D/13GO/S: 941.4M · as of 3 Aug 2026 · SEC cover page
Insiders & Institutional Holders
52-Week Range
$783.85$1321.21
$1279.00(92nd percentile)
Volume
Average Daily Volume2.32M
2.28M today vs 2.32M avg(-2%)

30d Avg

2.32M

60d Avg

2.34M

90d Avg

2.51M

Earnings
Dividend History
TTM Yield
0.53%
Paid quarterly
Annual (LTM)
$6.69
Latest
$1.7300
Aug 14, 26
5Y Growth
+15.25%
per year
Compliance Status
Loading compliance data...